Biotech

Latest Articles

Cassava spends $40M over supposedly misleading Alzheimer's update

.Cassava Sciences has actually agreed to pay out $40 million to solve an examination right into case...

Merck bags alternatives on Evaxion's AI-designed injection prospects

.Merck &amp Co. has picked up options on 2 Evaxion Biotech vaccine prospects, paying for $3.2 millio...

Enanta's RSV antiviral crushes popular load in problem research

.Enanta Pharmaceuticals has actually connected its respiratory syncytial infection (RSV) antiviral t...

Biogen cans SAGE-324 collaboration after important shake fall short

.Biogen has actually administered the final ceremonies to its own partnership with Sage Therapies on...

AbbVie Parkinson's drug from $8.7 B Cerevel buyout credit ratings

.On the exact same time that some Parkinson's ailment medicines are actually being actually called i...

Arch closes $3B-plus fund to nurture biopharma startups

.On the heels of a $3 billion fund from Bain Funding Life Sciences, Arch Venture Partners is actuall...

Orion to utilize Aitia's 'digital doubles' to find brand-new cancer cells drugs

.Finnish biotech Orion has actually spied potential in Aitia's "digital identical twin" technician t...

Windtree's shock med raises high blood pressure in latest stage 2 succeed

.While Windtree Therapeutics has actually struggled to grow the economic origins needed to have to e...

2 cancer cells biotechs merge, developing international footprint

.OncoC4 is actually taking AcroImmune-- as well as its internal scientific manufacturing capacities-...

Amgen files initial phase 3 gain for $400M chronic eczema medicine

.Amgen has actually discussed (PDF) the initial period 3 data on its $400 million chronic eczema med...

Biogen, UCB report period 3 lupus gain after stopping working earlier trial

.Biogen and also UCB's rely on developing right into phase 3 astride a broken research hopes to have...

Aptadir really hopes brand new RNA inhibitors can turn around tricky cancers cells

.Italian biotech Aptadir Rehabs has launched with the promise that its own pipe of preclinical RNA p...

Wave surfs DMD results to regulators' doors, sending out stock up

.Wave Life Sciences has actually fulfilled its own goal in a Duchenne muscle dystrophy (DMD) study, ...

Sanofi picks brand new CSO from in-stealth biotech

.After a handful of years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, occupyin...

Achilles drops tissue treatment program, prepares for discharges after skipping 'office feasibility' objectives

.Achilles Rehabs has actually shreded its approach. The English biotech is actually stopping work on...

Aligos advertises stage 2 MASH win, lowering liver fat as much as 46%

.Aligos Therapeutics is actually trumpeting a midstage gain in metabolic-dysfunction associated stea...

Basilea ratings $268M BARDA funding for antifungals, antibiotics

.Basilea Pharmaceutica's job establishing brand new antifungals has actually acquired a substantial ...

Capricor sells Europe civil rights to late-stage DMD therapy for $35M

.Possessing already gathered up the U.S. legal rights to Capricor Therapeutics' late-stage Duchenne ...

FDA fragments adcomm for Applied's uncommon ailment medication

.After pushing back the decision date for Applied Rehabs' metabolic condition drug govorestat, the F...

Novo inks $600M NanoVation bargain to analyze hereditary drugs ex-liver

.Novo Nordisk is proceeding its press in to genetic medicines, consenting to compensate NanoVation T...